Oncodesign Overview

  • Founded
  • 1995
Founded
  • Status
  • Public
  • Employees
  • 235
Employees
  • Stock Symbol
  • ALONC
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $14.22
  • (As of Friday Closing)

Oncodesign General Information

Description

Oncodesign SA is a France-based biotechnology company engaged in conducting research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It also offers integrated drug discovery services; in vitro and in vivo pharmacology services for proof of concept stage; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Discovery Tools (Healthcare)
Therapeutic Devices
Stock Exchange
PAR
Primary Office
  • 20 rue Jean Mazen
  • B.P. 27627
  • 21076 Dijon
  • France
+33 03 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncodesign Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.22 $14.42 $10.43 - $18.90 $96.9M 6.81M 10.4K $0.35

Oncodesign Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 89,839 89,839 72,724 54,835
Revenue 33,738 33,738 34,281 28,078
EBITDA 3,546 3,546 3,118 (2,825)
Net Income 2,397 2,397 1,819 (3,717)
Total Assets 72,574 72,574 44,418 45,291
Total Debt 33,655 33,655 13,914 15,318
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncodesign Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncodesign‘s full profile, request access.

Request a free trial

Oncodesign Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oncodesign SA is a France-based biotechnology company engaged in conducting research and development work on new therape
Biotechnology
Dijon, France
235 As of 2020
000.00
00.00 0000-00-00
00000000 000.00

00000000

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000 000000000
Nottingham, United Kingdom
000 As of 0000
0000000 0000

00000000

ate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
000000000 00000 (0000000000)
Hackensack, NJ
000 As of 0000
000.00
000000 - 000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncodesign Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom 000 0000000 0000
000000000 00000000 Formerly VC-backed Hackensack, NJ 000 000.00 000000 - 000 000.00
000000000 Formerly PE-Backed Freiburg, Germany 000000&0
00000000 Formerly VC-backed San Diego, CA 000 00000 000000&0 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
To view Oncodesign’s complete competitors history, request access »

Oncodesign Executive Team (13)

Name Title Board Seat Contact Info
Philippe Genne Ph.D Founder, Chairman & Chief Executive Officer
Arnaud Lafforgue Chief Financial and Administrative Officer
Jan Hoflack Chief Scientific and Operating Officer
Jonathan Ewing Director, Business Development
Olivier Duchamp Director Scientific Partnerships and Technology Transfer
You’re viewing 5 of 13 executive team members. Get the full list »

Oncodesign Board Members (1)

Name Representing Role Since
Karine Lignel Crédit Mutuel Innovation Board Member 000 0000
To view Oncodesign’s complete board members history, request access »

Oncodesign Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncodesign Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncodesign‘s full profile, request access.

Request a free trial

Oncodesign Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 (000 31-Aug-2017 000000000000000000 Pharmaceuticals 00000000 00000 00.0
GlaxoSmithKline (Francois Hyafil) 01-Dec-2016 Corporate Asset Purchase Buildings and Property 00000000 00000 00.0
To view Oncodesign’s complete investments and acquisitions history, request access »